← Eichor
Study identifier: NCT05493267 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Exploratory Study of Vγ2Vδ2 T Lymphocyte-based Immunotherapy for MDR-TB

Condition: MDR-TB · Immunotherapy  ·  Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

PhasePhase 4
Planned participants30
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

A Exploratory Study of drug combination (zoledronic acid/interleukin 2) that specifically amplifies Vγ2Vδ2 T cells in combination with anti-tuberculosis chemotherapy for the treatment of MDR-TB.

This description comes directly from the study's public registry record.

Talk to the study team

Sha Wei  ·  +8602165115006  ·  13671758200@126.com

Liu Yidian  ·  +8602165115006  ·  13816676933@139.com

Always discuss trial participation with your own doctor first.

Locations (2)

Shanghai Pulmonary Hospital, Shanghai, ChinaShanghai, ChinaRecruiting
Shanghai Pulmonary HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05493267